Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis.

HER2/ERBB2-overexpressing breast cancers targeted effectively by the small-molecule kinase inhibitor lapatinib frequently acquire resistance to this drug. In this study, we employed explorative mass spectrometry to profile proteome, kinome, and phosphoproteome changes in an established model of lapatinib resistance to systematically investigate initial inhibitor response and subsequent reprogramming in resistance. The resulting dataset, which collectively contains quantitative data for >7,800 proteins, >300 protein kinases, and >15,000 phosphopeptides, enabled deep insight into signaling recovery and molecular reprogramming upon resistance. Our data-driven approach confirmed previously described mechanisms of resistance (e.g., AXL overexpression and PIK3 reactivation), revealed novel pharmacologically actionable targets, and confirmed the expectation of significant heterogeneity in molecular resistance drivers inducing distinct phenotypic changes. Furthermore, our approach identified an extensive and exclusively phosphorylation-mediated reprogramming of glycolytic activity, supported additionally by widespread changes of corresponding metabolites and an increased sensitivity towards glycolysis inhibition. Collectively, our multi-omic analysis offers deeper perspectives on cancer drug resistance and suggests new biomarkers and treatment options for lapatinib-resistant cancers. Cancer Res; 77(8); 1842-53. ©2017 AACR.

[1]  E. Wiemer,et al.  The spliceosome as target for anticancer treatment , 2008, British Journal of Cancer.

[2]  K. Carraway,et al.  Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. , 2008, Cancer research.

[3]  Maxime Caron,et al.  ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer , 2016, Nature Communications.

[4]  J. Camonis,et al.  A yeast two‐hybrid study of human p97/Gab2 interactions with its SH2 domain‐containing binding partners , 2001, FEBS letters.

[5]  M Tan,et al.  Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth , 2009, Oncogene.

[6]  Graham Ball,et al.  Untangling the ATR‐CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer , 2015, Molecular oncology.

[7]  S. Asa,et al.  The breast cancer susceptibility FGFR2 provides an alternate mode of HER2 activation. , 2015, Oncogene.

[8]  Hua Guo,et al.  Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways , 2011, Nature Medicine.

[9]  R. Schiff,et al.  Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells , 2015, Cell cycle.

[10]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[11]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[12]  Lei Wang,et al.  RON confers lapatinib resistance in HER2-positive breast cancer cells. , 2013, Cancer letters.

[13]  M. Guarino.  Src signaling in cancer invasion , 2010, Journal of cellular physiology.

[14]  Yun Wu,et al.  Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. , 2011, Cancer research.

[15]  L. Korotchkina,et al.  Probing the Mechanism of Inactivation of Human Pyruvate Dehydrogenase by Phosphorylation of Three Sites* , 2001, The Journal of Biological Chemistry.

[16]  D. Hanahan,et al.  Hijacking the Neuronal NMDAR Signaling Circuit to Promote Tumor Growth and Invasion , 2013, Cell.

[17]  S. Hanash,et al.  EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. , 2016, Cancer research.

[18]  Heiner Koch,et al.  Comprehensive and Reproducible Phosphopeptide Enrichment Using Iron Immobilized Metal Ion Affinity Chromatography (Fe-IMAC) Columns , 2014, Molecular & Cellular Proteomics.

[19]  William Pao,et al.  Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase , 2011, Proceedings of the National Academy of Sciences.

[20]  M. Hagiwara,et al.  Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA , 2007, Nature Chemical Biology.

[21]  Joel Greshock,et al.  Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. , 2009, Cancer research.

[22]  D. Carling,et al.  Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia , 2000, Current Biology.

[23]  S. Braun,et al.  Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors , 2013, Leukemia.

[24]  C. Le Page,et al.  PRP4K is a HER2-regulated modifier of taxane sensitivity , 2015, Cell cycle.

[25]  Naoto T. Ueno,et al.  P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.

[26]  G. Dellaire,et al.  Estrogen receptor alpha (ESR1)-signaling regulates the expression of the taxane-response biomarker PRP4K. , 2016, Experimental cell research.

[27]  Carlos L Arteaga,et al.  Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network , 2007, Clinical Cancer Research.

[28]  Jonathan A. Cooper,et al.  Three glycolytic enzymes are phosphorylated at tyrosine in cells transformed by Rous sarcoma virus , 1983, Nature.

[29]  B. Kuster,et al.  Evaluation of Kinase Activity Profiling Using Chemical Proteomics. , 2015, ACS chemical biology.

[30]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[31]  A. Bode,et al.  Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib , 2014, Cell cycle.

[32]  J. Gustafsson,et al.  ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway , 2014, Oncogene.

[33]  Sean J. Humphrey,et al.  Protein Phosphorylation: A Major Switch Mechanism for Metabolic Regulation , 2015, Trends in Endocrinology & Metabolism.

[34]  Lu Xie,et al.  Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. , 2010, Cancer research.

[35]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[36]  C. Lange,et al.  Progesterone receptor action: defining a role in breast cancer , 2011, Expert review of endocrinology & metabolism.

[37]  W. Hahn,et al.  PRKACA Mediates Resistance to HER2-Targeted Therapy in Breast Cancer Cells and Restores Anti-Apoptotic Signaling , 2014, Oncogene.

[38]  Z. Fei,et al.  Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells. , 2016, Molecular bioSystems.

[39]  Tyler J Moss,et al.  The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells , 2012, Molecular systems biology.

[40]  F. Khuri,et al.  Tyrosine Phosphorylation of Lactate Dehydrogenase A Is Important for NADH/NAD+ Redox Homeostasis in Cancer Cells , 2011, Molecular and Cellular Biology.

[41]  Reinout Raijmakers,et al.  Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics , 2009, Nature Protocols.

[42]  P. Hegde,et al.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[44]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[45]  Alexander Levitzki,et al.  Therapeutic destruction of insulin receptor substrates for cancer treatment. , 2013, Cancer research.

[46]  T. Shimokawa,et al.  SHIP2 and its involvement in various diseases , 2010, Expert opinion on therapeutic targets.

[47]  G. Omenn,et al.  Proteomic characterization of novel alternative splice variant proteins in human epidermal growth factor receptor 2/neu-induced breast cancers. , 2010, Cancer research.

[48]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[49]  Jeff S. Jasper,et al.  ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. , 2016, Cell reports.

[50]  C. J. O’Donnell,et al.  Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/α-ketoglutarate–dependent dioxygenase , 2014, Proceedings of the National Academy of Sciences.

[51]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[52]  B. Kuster,et al.  Optimized chemical proteomics assay for kinase inhibitor profiling. , 2015, Journal of proteome research.

[53]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[54]  G. Mills,et al.  Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition , 2011, Oncogene.

[55]  A. Kazlauskas,et al.  Lactate Engages Receptor Tyrosine Kinases Axl, Tie2, and Vascular Endothelial Growth Factor Receptor 2 to Activate Phosphoinositide 3-Kinase/Akt and Promote Angiogenesis* , 2013, The Journal of Biological Chemistry.